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Abstract
Background: Primary aldosteronism (PA) affects approximately 5 to 10% of all patients with arterial hypertension and
is associated with an excess rate of cardiovascular complications that can be significantly reduced by a targeted treatment.
There exists a general consensus that the aldosterone to renin ratio should be used as a screening tool but valid data
about the accuracy of the aldosterone to renin ratio in screening for PA are sparse. In the Graz endocrine causes of
hypertension (GECOH) study we aim to prospectively evaluate diagnostic procedures for PA.
Methods and design: In this single center, diagnostic accuracy study we will enrol 400 patients that are routinely
referred to our tertiary care center for screening for endocrine hypertension. We will determine the aldosterone to
active renin ratio (AARR) as a screening test. In addition, all study participants will have a second determination of the
AARR and will undergo a saline infusion test (SIT) as a confirmatory test. PA will be diagnosed in patients with at least
one AARR of ≥ 5.7 ng/dL/ng/L (including an aldosterone concentration of ≥ 9 ng/dL) who have an aldosterone level of ≥
10 ng/dL after the saline infusion test. As a primary outcome we will calculate the receiver operating characteristic curve
of the AARR in diagnosing PA. Secondary outcomes include the test characteristics of the saline infusion test involving a
comparison with 24 hours urine aldosterone levels and the accuracy of the aldosterone to renin activity ratio in
diagnosing PA. In addition we will evaluate whether the use of beta-blockers significantly alters the accuracy of the AARR
and we will validate our laboratory methods for aldosterone and renin.
Conclusion: Screening for PA with subsequent targeted treatment is of great potential benefit for hypertensive patients.
In the GECOH study we will evaluate a standardised procedure for screening and diagnosing of this disease.
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Background
Primary aldosteronism (PA) is characterised by aldoster-
one concentrations that are inappropriately high in rela-
tion to the activity of the renin-angiotensin system and
that are not adequately suppressible by sodium loading
[1-3]. Recent studies have shown that PA, with its two
main subtypes aldosterone producing adenoma (APA)
and bilateral adrenal hyperplasia (BAH), is the most com-
mon cause of secondary hypertension with a prevalence
of approximately 5–10% among all hypertensive patients
and an even higher prevalence among selected patients
with advanced stages of hypertension and resistant hyper-
tension [1-3]. Importantly, patients suffering from PA
have, independent of blood pressure, an increased risk of
cardiovascular diseases and renal damage when compared
to patients with essential hypertension [4-7]. Therefore,
screening for PA is important for hypertensive patients
because detection of PA offers the opportunity for a tar-
geted and effective treatment that significantly reduces the
excess cardiovascular risk in patients with PA [7,8]. After
removal of the affected adrenal gland, patients with APA
are cured from hypertension in approximately half of the
cases with an improvement of hypertension in the
remainder [1-3]. This surgical therapy is also considered
cost-effective [9]. Patients with BAH respond well to drug
therapy with mineralcorticoid receptor antagonists [1-
3,7].
Despite a wide acceptance of the aldosterone to active
renin ratio (AARR) and the aldosterone to renin activity
ratio (ARR) in screening for PA, the accuracy of these tests
is still not well documented [10], leading to many contro-
versies and discrepancies in the use of AARR and ARR as a
screening tool for PA which can be attributed to several
causes: (1) There exists no generally accepted "gold stand-
ard" or "reference standard" for the diagnosis of PA,
mainly because APA but not BAH can be unambiguously
diagnosed (APA can be diagnosed by cure or improve-
ment of arterial hypertension after surgical removal of an
histopathologically confirmed adrenal adenoma). (2) In
most diagnostic studies in this field only patients with a
positive result of the screening test were referred to the
chosen "reference standard test", which may be responsi-
ble for a verification bias with an overestimated accuracy
of the screening test[10]. (3) The results of the AARR and/
or ARR are hardly comparable between different laborato-
ries. Comparative studies have partially shown signifi-
cantly different inter-laboratory results, mainly depending
on the laboratory methods (assays) used [1-3,11]. (4) The
AARR and/or the ARR are also influenced by several other
factors including e.g. medications, age, time of blood
sampling, posture and dietary salt intake. It still needs to
be clarified whether these above mentioned factors, in
particular the use of beta-blockers, that were shown to
decrease renin levels, significantly alter the accuracy of the
AARR and/or ARR in screening for PA [1-3,12,13]. It
should also be pointed out that dietary salt loading has a
significant impact on the renin-angiotensin aldosterone
system (RAAS) with complex interactions and is thus a
potential confounder for diagnostic procedures for PA
[14], which are largely performed without considering
dietary sodium intake [1]. In summary, previous studies
reveal great discrepancies concerning the blood sampling
conditions and laboratory methods for the determination
of the AARR and/or ARR. Hence there is an urgent need for
further evaluation and development of standardised and
practicable diagnostic procedures for the detection of PA.
In our study we apply a standardised diagnostic procedure
for PA in hypertensive patients that was derived from the
most valid currently available data about this topic [1-3].
Our main study aims are (1) to test the accuracy of the
AARR in screening for PA (primary outcome), (2) to test
the accuracy of the saline infusion test (SIT) and (3) to
evaluate whether the use of beta-blockers significantly
alters the accuracy of the AARR as a screening test for PA.
(4) In the first 100 patients of our study we aim to com-
pare our laboratory methods for aldosterone and renin
with other widely used and validated assays and (5) we
will calculate the accuracy of the ARR in diagnosing PA
and compare it with the accuracy of the AARR. (6) We will
also evaluate the test characteristics of the SIT in compar-
ison with PA diagnosis based on 24 hours urine aldoster-
one levels.
Methods and design
Study design
The Graz endocrine causes of hypertension (GECOH)
study is a single center diagnostic accuracy study to deter-
mine the sensitivity and specificity of the AARR in screen-
ing for PA (Figure 1). The GECOH study was designed by
adhering to the recommendations of the statement for
reporting studies of diagnostic accuracy (STARD) and the
Declaration of Helsinki [15].
Study population and study setting
The study will be performed at an outpatient clinic of a
tertiary care center (Department of Internal Medicine,
Division of Endocrinology and Nuclear Medicine, Medi-
cal University of Graz, Austria). The study population
consists of patients who are routinely referred to our
department for screening for endocrine hypertension. The
patient management and disease classification will be
done by experienced endocrinologists.
Inclusion/Exclusion criteria
Medications that significantly interfere with aldosterone
mediated effects including spironolactone, canrenoate,
eplerenone, amiloride and triamteren have to be stopped
at least 4 weeks before screening procedures for theBMC Endocrine Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6823/9/11
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GECOH study will be carried out because it is generally
recommended to stop these medications before testing for
PA [1].
Inclusion criteria
The main inclusion criterion is arterial hypertension
defined according to recent guidelines as an average office
blood pressure on at least two occasions of systolic ≥ 140
and/or diastolic ≥ 90 mmHg or a mean 24 ambulatory
blood pressure of systolic ≥ 125 and/or diastolic ≥ 80, or
a home blood pressure of systolic ≥ 130 and/or diastolic ≥
85 or ongoing antihypertensive treatment that was initi-
ated due to arterial hypertension [16,17]. Further inclu-
sion criteria are age of ≥ 18 years and written informed
consent.
Exclusion criteria
Exclusion criteria were chosen to avoid inclusion of
patients whose AARR is likely to be significantly biased by
underlying diseases or medications. As a matter of course
patients in whom the SIT may be contraindicated will be
excluded too [1]. Accordingly, the exclusion criteria are a
glomerular filtration rate (GFR) according to the MDRD
formula < 30 ml/min/1.73 m2 [18], severe hepatic failure
(Child-Pugh class B or C), severe heart failure with NYHA
class 3 or 4, acute coronary syndrome within the last two
weeks, immunosuppressive therapy, glucocorticoid ther-
apy, ongoing chemotherapy, pregnancy and any other dis-
ease with an estimated life expectancy below 1 year.
Patients that are initial eligible for the GECOH study but
who meet any of the exclusion criteria during the study
will also be excluded.
Blood sampling conditions
For all blood samplings within this study, each patient
will be informed to come fasting (12 hour overnight fast).
Smoking and intake of any antihypertensive drug should
also be avoided in the morning before blood collection.
Flow-chart of the GECOH study including diagnostic criteria for primary aldosteronism and other forms of hypertension Figure 1
Flow-chart of the GECOH study including diagnostic criteria for primary aldosteronism and other forms of 
hypertension. See text for detailed information.
1. Measurement of the AARR = screening test
2. Measurement of the AARR and SIT
Stop of beta-blocker intake after 1. study visit
2-6 weeks interval between 1. and 2. study vist
Primary aldosteronism Other forms of hypertension
Diagnostic criteria for primary
aldosteronism:
At least one AARR of  5.7 ng/dL/ng/L 
including an aldosterone level of  9 ng/dL
plus
Aldosterone concentrations of  10 ng/dL
after the SIT
Diagnostic criteria for other forms of 
hypertension:
All patients, who do not fulfil the criteria for
primary aldosteronism
1. Study visit
2. Study visitBMC Endocrine Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6823/9/11
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Blood samplings for the determinations of the AARR and
ARR will be done in the morning (8:00 to 11:00) after the
patients have been seated for 10 minutes. Extreme care
will be taken to avoid haemolysis and prolonged stasis.
Screening test
The AARR (aldosterone in ng/dL divided by active renin
concentration in ng/L) is used as the screening test for PA
[1-3]. An elevated AARR indicates that the aldosterone
secretion is inappropriately high with regard to its princi-
ple trophin renin [1-3]. The chosen cut-off value for a pos-
itive screening test of an AARR of ≥ 5.7 (corresponding to
an ARR of 30 expressed as aldosterone in ng/dl divided by
plasma renin activity [PRA] in ng/ml/h) is in line with
recent guidelines (1). Furthermore, only patients with an
aldosterone of ≥ 9 ng/dL, in addition to an AARR of ≥ 5.7,
are considered to have a positive screening test because a
recent study has shown that there were no patients with
PA that had aldosterone levels below this threshold [19].
Reference standard test
All patients will undergo the reference standard test that
consists of two determinations of the AARR (including the
AARR of the screening test) plus the results of the SIT. The
rationale for using two measurements of the AARR derives
from the observations of Tanabe et al who have shown
that repeated determinations of the AARR are necessary to
avoid overlooking of patients with PA [20]. In the
GECOH study the second determination of the AARR will
be done 2–6 weeks after the screening test and is immedi-
ately followed by the SIT on the same day.
The SIT is a safe, simple and relatively inexpensive con-
firmatory test for patients with a positive screening test
[1,21]. The SIT is widely used and shows a good agree-
ment with the fludrocortisone suppression test (FST),
which is by some authors considered as the gold standard
test for diagnosing PA [21]. However, the FST requires
hospitalization for 4 days and intake of fludrocortisone
tablets together with salt and potassium supplementation
and is thus less practicable [21]. In the morning of the SIT
blood will be drawn for the second determination of the
AARR after seating for 10 minutes. Then the patient will
stay in a recumbent position for one hour. Afterwards the
SIT is performed by infusing 2 litres of 0.9% saline i.v.
over 4 hours starting at 9:00–9:30 [1]. After the saline
infusion, blood sampling will be performed and patients
with an aldosterone concentration ≥ 10 ng/dL are consid-
ered to have a positive SIT. This cut-off value is in line with
the recommendation of Diederich et al for our specific
aldosterone assay [22] and is supported by previous
results from Schirpenbach et al [11].
In addition, we will also measure 24 hours urine sodium
and aldosterone levels in the morning before the SIT. This
will be done because a high chronic oral sodium loading
indicated by 24 hours urine sodium concentrations of
over 200 mEq [23] is part of an established confirmatory
test, in which the diagnosis of PA is based on 24 hours
urine aldosterone concentration above 12 μg/24 h[1,24]
Considering that according to recent guidelines we do not
make any recommendations concerning salt intake of our
study participants it is likely that a significant proportion
of our study population will have a 24 hours urine
sodium level above 200 mEq[23] In such patients we will
compare the SIT with the results of the 24 hours urine
aldosterone measurements in order to evaluate the accu-
racy of the SIT in the setting of high dietary sodium load.
Use of medications in the GECOH study
Except of drugs that significantly interfere with aldoster-
one mediated effects and that must be withdrawn at least
four weeks before inclusion into the GECOH study, the
remainder medical therapy will not be altered for the
screening test. This approach is supported by previous
findings showing that concomitant antihypertensive
medication does not adversely affect the test accuracy of
the ARR in diagnosing PA [24]. However, this issue still
remains to be addressed for the AARR and warrants con-
firmation in further studies because several medications
have been shown to alter the aldosterone to renin ratio
[1]. Beta-blockers are, apart from the above mentioned
drugs that interfere with aldosterone mediated effects, the
medications that are considered to have the greatest
impact on the aldosterone to renin ratio[12,13] This effect
of beta-blockers on the AARR is strongly driven by their
effect on renin levels with minor effects on aldosterone
concentrations [1]. To evaluate whether the use of beta-
blockers significantly alters the accuracy of the AARR in
screening for PA we will stop the intake of beta-blockers
in all patients after the screening test in order to have a sec-
ond AARR determination that is not potentially biased by
beta-blocker intake and that can be compared with the
screening test with regard to its sensitivity and specificity
in detecting PA. In case of poor blood pressure control
after cessation of beta-blockers we will either increase the
dose of other pre-existing antihypertensive drugs or we
will initiate a therapy with verapamil, hydralazine, pra-
zosin, doxazosin and/or terazosin, that have only minor
influences on the AARR [1].
Diagnostic criteria
According to the results of the reference standard test we
have established the following criteria for PA and for other
forms of arterial hypertension:
Patients with at least one AARR ≥ 5.7 including an aldos-
terone levels ≥ 9 ng/dL who have aldosterone concentra-
tions of ≥ 10 ng/dL after the SIT will be diagnosed as
having PA. These criteria are in line with the general rec-BMC Endocrine Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6823/9/11
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ommendation that the diagnosis of PA should always be
based on a positive screening test (AARR) that must be
confirmed by a confirmatory test (SIT) [1-3]. Patients who
do not fulfil the above mentioned criteria for PA will be
diagnosed as having other forms of arterial hypertension.
Laboratory methods
All blood samples taken will be centrifuged within 1 hour
after sampling and will be either immediately stored at -
20°Celsius until analysis, that will be done on a weekly
basis, or measured at least 4 hours after blood collection.
Before analysis or freezing all samples will be kept at room
temperature, except of the samples for determination of
aldosterone, which will be kept at 4°Celsius.
Active renin concentrations will be determined according
to manufacturers instructions from EDTA plasma by a
"RENIN III GENERATION" (GEN. III) RIA assay (Renin
IRMA RIA-4541, DRG Instruments GmbH, Marburg, Ger-
many), that has been calibrated against a WHO standard
[25]. The lower detection limit of this assay is < 1.0 ng/L
and renin concentrations of 1.0 ng/L or lower are all set
1.0 ng/L. Intra-assay and inter-assay coefficients of varia-
tion of this assay are 0.6 to 4.5 and 2.7 to 14.5%, respec-
tively. According to recent guidelines the conversion
factor from a PRA level in ng/ml/h to renin in pg/ml is 5.2
and the conversion factor from PRA in ng/ml/h to renin in
mU/L is 8.2 [1]. These latter conversion factors were rec-
ommended for a II generation RIA (Bio-Rad Renin II RIA)
and these II generation RIAs are in excellent agreement
with our III generation renin assay, so that we adopted
these conversion factors [1,25].
Aldosterone from EDTA plasma will be determined
according to manufacturers instructions by RIA (Active
Aldosterone RIA DSL-8600, Diagnostic Systems Laborato-
ries, Inc., Webster, Texas, USA) [11]. The intra-assay and
inter-assay coefficients of variations of this assay are 3.3 to
4.5 and 5.9 to 9.8%, respectively.
Measurements of plasma renin activity, that are based on
the determination of angiotensin I whose conversion
from angiotensinogen is catalyzed by renin, will be per-
formed in blood samples of the screening test of the first
100 patients included in the GECOH study. Renin activity
in EDTA plasma will be measured by an angiotensin-I-RIA
(RENCTK, Dia Sorin, Italy) according to manufacturers'
instructions. In the same subset of patients (first 100
patients of this study) we will also determine aldosterone
levels in serum of the screening test by liquid chromatog-
raphy – tandem mass spectrometry according to the
method by Turpeinen et al. [26]. Measurements of 24
hours urine aldosterone levels will also be done by means
of liquid chromatography – tandem mass spectrometry
[27]. As part of the clinical routine, additional laboratory
measurements for other causes of arterial hypertension
(e.g. for pheochromocytoma or Cushing's disease) and
cardiovascular risk assessments may also be performed in
patients of the GECOH study. All laboratory measure-
ments will be done at the laboratory of the Medical Uni-
versity of Graz, Austria.
Sample size
Sample size calculation was carried out for our primary
outcome (accuracy of the AARR in screening for PA)
according to the previously published method by Jones et
al [28]. This method is used to calculate the sample size
required to estimate an expected level of sensitivity with a
predefined degree of precision (confidence interval) [28].
According to previous results of hypertensive patients
referred to tertiary care centres we estimated a prevalence
of PA of 20% among our study population [1-3,29,30].
Using this disease prevalence of 20% and an expected
level of sensitivity of the AARR in screening for PA of 95%
[3,22] with a confidence interval of 5% we calculated a
required study sample size of 365 study participants. To
compensate for drop-outs during the study and for
patients with incomplete data (= patients with incomplete
reference standard test results) that have to be excluded we
plan to enrol 400 patients in our study. Considering the
current number of patients that are regularly referred to
our outpatient clinic for screening for endocrine hyperten-
sion and considering the feasibility to perform the SIT and
the other diagnostic procedures at our clinic we plan to
recruit these 400 patients within 3 years.
Statistical analysis
Receiver-operating characteristics (ROC) curves will be
calculated and graphed to show the characteristics of the
AARR as a screening test for PA. In addition, we will also
present the ROC curve for the SIT in diagnosing PA. For
patients with initial beta-blocker therapy we will graph
and compare the ROC curve for the AARR before (screen-
ing test) and after (second AARR determination) discon-
tinuation of beta-blockers. We will also show the ROC
curve for the ARR and we will compare the ROC curve for
the AARR and ARR in diagnosing PA. ROC curves will be
compared by the method of DeLong [31]. Correlation
analysis will be performed of active renin concentrations
and plasma renin activity. Apart from this, we will also
perform the correlation analysis of aldosterone concentra-
tions determined by RIA and by liquid chromatography –
tandem mass spectrometry and we will show the Bland-
Altman plot of the aldosterone values obtained by these
two methods [32]. In patients with 24 hours urine sodium
concentrations above 200 mEq, we will present the sensi-
tivity and specifity of the SIT for diagnosing PA by using
24 hours urine aldosterone levels as the reference test. Sta-
tistical analyses will be performed by Analyse-it software
(Analyse-it software, Ltd., Leeds, UK) [33] and by the SPSSBMC Endocrine Disorders 2009, 9:11 http://www.biomedcentral.com/1472-6823/9/11
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16.0 statistical package (SPSS, Inc., Chicago, IL, USA). A p-
value below 0.05 will be considered statistically signifi-
cant.
Ethical issues
Our study population consists of patients with a high
probability of PA, thus justifying an extensive screening
procedure for this disease in view of the fact that patients
with PA are at excess risk of cardiovascular disease which
can be significantly reduced by a targeted treatment in dis-
eased patients [1]. The SIT is considered a safe confirma-
tory test and previous studies have shown no significant
side effects apart from occasionally observed increases in
blood pressure that could all be well controlled [1-
3,21,34]. Towards this, we want to note that blood pres-
sure and heart rate will be regularly (all 30 minutes) meas-
ured during the SIT. We plan to perform the SIT in all
study participants because this test can only be accurately
validated if patients with and without PA are tested [10].
However, to avoid needless SIT in a relevant number of
patients without PA we will perform interim analyses after
the inclusion of 100 and 200 patients. If the proportion of
patients without any elevated AARR (AARR of ≥ 5.7
including an aldosterone levels ≥ 9 ng/dL) exceeds 75%
after inclusion of 100 patients and/or 50% after inclusion
of 200 patients, we will stop to perform the SIT in such
study participants. Then we would, until the end of the
GECOH study, perform the SIT only in patients with at
least one elevated AARR. The GECOH study was approved
by the ethics committee at the Medical University of Graz,
Austria.
Discussion
The high prevalence among hypertensive patients and the
great benefit of a targeted treatment in patients suffering
from PA underline the importance of screening for this
disease. The results of the GECOH Study will significantly
add to the currently rare data of valid prospective studies
that evaluate standardised procedures for screening and
diagnosing PA.
A limitation of our study is that we will include patients
that are referred to a tertiary care center, thus comprising
a highly selected study population, and our results may
therefore not be generalizable to less selected patients or
even patients in primary care settings. Another main lim-
itation is that the reference standard test (2 determina-
tions of the AARR plus the SIT) for the diagnosis of PA is
not independent from the results of the screening test
because it even incorporates the AARR of the screening
test. This may be responsible for an overestimation of the
accuracy of the AARR. Similarly, the accuracy of the SIT
may be overestimated because it is also part of the refer-
ence standard test. Apart from this, it should be acknowl-
edged that the current diagnostic procedures for PA are
based on the consideration to show that aldosterone
secretion is relatively autonomous from the renin-angi-
otensin system and from sodium loading. It should, how-
ever, be pointed out that the regulation of aldosterone
secretion is a complex process with many influence factors
that still need to be further explored in detail [35]. A main
problem in this field is to differentiate whether relevant
alterations of renin and/or aldosterone levels are mainly
driven by dysregulations of the RAAS system itself or are
secondary due to other environmental and/or genetic
pathologies leading to dyshomeostasis of sodium balance
[14,36]. Of particular interest are also ethnic differences
regarding the regulation of sodium balance and the RAAS
because previous studies suggest that patients of African
ancestry might be predisposed to low renin levels
[14,23,37]. We therefore do not restrict our study popula-
tion to certain ethnicities but the low proportion of e.g.
persons with African ancestry in Austria may limit our
ability to detect ethnic differences.
The main strengths of the GECOH study are the standard-
ised blood sampling conditions, the comparison of differ-
ent laboratory methods with the parallel evaluation of the
AARR and ARR in diagnosing PA and the fact that all
patients are scheduled to undergo the screening and the
reference standard test. Apart from this, the comparison of
the SIT with the results of the 24 hours urine aldosterone
measurements will further improve our knowledge about
the influence of chronic salt loading on diagnostic proce-
dures for PA.
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